ClinicalThought

Share

Program Content

Activities

  • Adv <i>EGFR+</i> NSCLC in 2021
    What Everyone Should Know About Management of Advanced EGFR-Mutated Non-Small-Cell Lung Cancer in 2021
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 08, 2021

    Expires: March 07, 2022

  • Adv <i>EGFR</i>+ NSCLC: EU/US Perspectives
    Regional Perspectives on Current Management of Advanced EGFR-Mutated Non-Small-Cell Lung Cancer
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 20, 2021

    Expires: April 19, 2022

  • Liquid Biopsy in <i>EGFR+</i> NSCLC
    My Thoughts on the Evolving Role of Liquid Biopsies in the Treatment of EGFR Mutation–Positive Advanced NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2021

    Expires: May 31, 2022

  • Barriers to Osimertinib
    First-line Osimertinib for EGFR-Mutated Advanced NSCLC: Barriers to Access and Future Directions
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 29, 2021

    Expires: July 28, 2022

Faculty

cover img faculity

Enriqueta Felip, MD

Head, Thoracic Oncology Unit
Oncology Service
Vall d Hebron University Hospital
Barcelona, Spain

cover img faculity

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

cover img faculity

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

cover img faculity

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Professor of Medicine
Division of Hematology and Oncology
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
Center for Thoracic Oncology
The Tisch Cancer Institute
Mount Sinai Health System
New York, New York

Provided by

ProCE Banner

Supporters

AstraZeneca